Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

The stock of clinical-stage biotech Amylyx Pharmaceuticals (NASDAQ: AMLX) was a hot item among investors over the past five trading days.One of its investigational medicines did very well in a late-stage clinical trial; this, combined with several subsequent analyst price target raises and the commencement of a secondary stock issue, drove Mr. Market to the shares. According to data compiled by S&P Global Market Intelligence, they ended the week with an almost 79% increase.On Tuesday, Amylyx published the topline results of a Phase 3 clinical trial of avexitide, a GLP-1 medication targeting post-bariatric hypoglycemia (low blood glucose levels after weight-loss surgery). Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool